BiPar Sciences Alternatives & Competitors
12 companies similar to BiPar Sciences — Innovative therapies harnessing the power of PARP inhibitors to combat advanced...
Companies similar to BiPar Sciences
OS Therapies
Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis an...
New York, United States
Apollomics
We are a biopharmaceutical company committed to the discovery and development of mono- and...
Foster City, United State...
Coeptis Therapeutics
A biopharmaceutical company developing innovative cell therapy platforms for patients with...
GLG Pharma
Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's...
Jupiter, United States
Rival Readout
Competing with BiPar Sciences? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Phoenix Molecular Designs
A clinical stage biopharmaceutical company designing precise cancer therapeutics to addres...
San Diego, United States
Seattle, United States
Oncorena AB
Developing a first-in-class treatment for advanced renal cancer
Lund, Sweden
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Australia
Cytimmune Sciences
Developing safer more effective therapies that can attack tumors on multiple fronts simult...
Rockville, United States
Merck & Co., Inc.
Merck develops and produces medicines, vaccines, biologic therapies and animal health prod...
AlloMek Therapeutics LLC
Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.
About BiPar Sciences
BiPar Sciences, based in Brisbane, CA, is a biotechnology company focused on developing innovative therapies utilizing PARP inhibitors to combat advanced cancers. The company's leading experimental drug, BSI-201, is currently undergoing mid-phase trials aimed at treating advanced breast cancer, ovarian cancer, and othe...
BiPar Sciences, PARP Inhibitors, Cancer Therapies, BSI-201, Oncology, Venture Capital, Acquisition, Sanofi-Aventis, Clinical Trials, Breast Cancer, Ovarian Cancer, Tumor Treatment, Drug Development, Pharmaceutical Industry
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around BiPar Sciences: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at BiPar Sciences on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 2 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
